Denali Therapeutics Inc. Common Stock
DNLIDenali Therapeutics Inc. (DNLI) is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases and other difficult-to-treat diseases of the central nervous system. Founded in 2015, Denali leverages its expertise in biology, engineering, and medicine to create innovative treatments aimed at crossing the blood-brain barrier to target underlying disease mechanisms. The company's pipeline includes investigational medicines for conditions such as Alzheimer's, Parkinson's, and ALS.
Company News
Denali Therapeutics announced it will sell its Rare Pediatric Disease Priority Review Voucher for $195 million following FDA approval of AVLAYAH, the first FDA-approved biologic designed to cross the blood-brain barrier. The proceeds will support advancement of Denali's clinical pipeline for lysosomal storage disorders and neurodegenerative disea...
Biogen and Denali Therapeutics announced that BIIB122 (DNL151), a LRRK2 inhibitor, failed to meet primary and secondary endpoints in the Phase 2b LUMA study for early-stage Parkinson's disease. The companies will discontinue development in idiopathic Parkinson's disease, though Denali will continue the Phase 2a BEACON study in LRRK2 variant carri...
Biogen and Denali Therapeutics announced that BIIB122 (DNL151), an investigational LRRK2 inhibitor, failed to meet primary and secondary endpoints in the Phase 2b LUMA study for early-stage Parkinson's disease. The drug did not slow disease progression compared to placebo. Both companies will discontinue development of BIIB122 in idiopathic Parki...
The oligonucleotides clinical trial landscape is expanding rapidly with 200+ companies developing 600+ pipeline drugs. Major players like Novartis, Alnylam Pharmaceuticals, Amgen, and WaVe Life Sciences are advancing promising therapies across various clinical stages. Approximately 20+ oligonucleotides are in late-stage development while 150+ are...
Privium Fund Management acquired 254,857 shares of Denali Therapeutics for approximately $5.07 million in Q1 2026, representing a new 1.02% position in their portfolio. The investment comes after the FDA granted accelerated approval for Denali's first commercial drug, Avlayah, which treats Hunter syndrome and validates their TransportVehicle plat...
